References
- Arzneimittel-Kompendium der Schweiz. Documed AG. Basel, Switzerland (2005).
- Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041), 1535–1541 (1996).
- Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin. Endocrinol. Metab. 85(11), 4118–4124 (2000).
- Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14), 1344–1352 (1999).
- McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. 344(5), 333–340 (2001).
- Stafford RS, Drieling RL, Hersh AL. National trends in osteoporosis visits and osteoporosis treatment, 1988–2003. Arch. Intern. Med. 164(14), 1525–1530 (2004).
- Borgstrom F, Johnell O, Jonsson B, Zethraeus N, Sen SS. Cost–effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34(6), 1064–1071 (2004).
- Brecht JG, Kruse HP, Felsenberg D, Mohrke W, Oestreich A, Huppertz E. Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int. J. Clin. Pharmacol. Res. 23(4), 93–105 (2003).
- Brecht JG, Kruse HP, Mohrke W, Oestreich A, Huppertz E. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int. J. Clin. Pharmacol. Res. 24(1), 1–10 (2004).
- Iglesias CP, Torgerson DJ, Bearne A, Bose U. The cost utility of bisphosphonate treatment in established osteoporosis. QJM 95(5), 305–311 (2002).
- Johnell O, Jonsson B, Jonsson L, Black D. Cost–effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21(5), 305–314 (2003).
- Kanis JA, Borgstrom F, Johnell O, Jonsson B. Cost–effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos. Int. 15(11), 862–871 (2004).
- McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48, 271–287 (2004).
- Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos. Int. 15(12), 1003–1008 (2004).
- Fleurence RL, Iglesias CP, Torgerson DJ. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos. Int. (2005) (In Press).
- Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13(4), 397–409 (1998).
- Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med. Decis. Making 13(4), 322–338 (1993).
- Sendi PP, Craig BA, Pfluger D, Gafni A, Bucher HC. Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. J. Eval. Clin. Pract. 5(3), 283–295 (1999).
- Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med. Care 43(6), 521–530 (2005).
- Urquhart J. Pharmionics: research on what patients do with prescription drugs. Pharmacoepidemiol. Drug Saf. 13(9), 587–590 (2004).
- Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin. Pharmacokinet. 44(6), 551–570 (2005).
- Philips Z, Ginnelly L, Sculpher M et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol. Assess. 8(36), 1 (2004).